$CGON News

CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run

CG Oncology to Present at Upcoming Investor Conferences in September

CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup

CG Oncology: Circling Back After Huge Rally

RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

CG Oncology: Priced To Perfection On Future Pipeline Success

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating